Serotonin transporter binding is reduced in seasonal affective disorder following light therapy

Acta Psychiatr Scand. 2016 Nov;134(5):410-419. doi: 10.1111/acps.12632. Epub 2016 Aug 24.

Abstract

Objective: To investigate the effects of light therapy on serotonin transporter binding (5-HTT BPND ), an index of 5-HTT levels, in the anterior cingulate and prefrontal cortices (ACC and PFC) during winter in seasonal affective disorder (SAD). 5-HTT BPND fluctuates seasonally to a greater extent in SAD relative to health. We hypothesized that in SAD, 5-HTT BPND would be reduced in the ACC and PFC following light therapy.

Methods: Eleven SAD participants underwent [11 C] DASB positron emission tomography (PET) scans to measure 5-HTT BPND before and after 2 weeks of daily morning light therapy.

Results: The primary finding was a main effect of treatment on 5-HTT BPND in the ACC and PFC (repeated-measures manova, F(2,9) = 6.82, P = 0.016). This effect was significant in the ACC (F(1,10) = 15.11 and P = 0.003, magnitude of decrease, 11.94%) and PFC (F(1,10) = 8.33, P = 0.016, magnitude of decrease, 9.13%). 5-HTT BPND also decreased in other regions assayed following light therapy (repeated-measures manova, F(4,7) = 8.54, P = 0.028) including the hippocampus, ventral striatum, dorsal putamen, thalamus and midbrain (F(1,10) = 8.02-36.94, P < 0.0001-0.018; magnitude -8.83% to -16.74%).

Conclusions: These results demonstrate that light therapy reaches an important therapeutic target in the treatment of SAD and provide a basis for improvement of this treatment via application of [11 C]DASB PET.

Keywords: light therapy; neuroimaging; prefrontal cortex; seasonal affective disorder; serotonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Gyrus Cinguli / metabolism
  • Humans
  • Male
  • Phototherapy / methods*
  • Positron-Emission Tomography / methods
  • Prefrontal Cortex / metabolism
  • Protein Binding
  • Seasonal Affective Disorder / metabolism
  • Seasonal Affective Disorder / therapy*
  • Serotonin Plasma Membrane Transport Proteins / metabolism*
  • Treatment Outcome

Substances

  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins